US Patent 7,435,745: Scope, Claim Scope Boundaries, and Competitive Patent Landscape
What does US 7,435,745 claim, in plain technical scope terms?
US 7,435,745 claims a combination treatment method for blood-borne tumors using:
- Thalidomide
- Dexamethasone
- A “treating” method based on administering an effective amount of thalidomide in combination with dexamethasone.
The independent claim is a method-of-treatment claim centered on the therapeutic regimen rather than a formulation or device.
Claim set (as provided)
| Claim |
Scope element added |
Key technical boundary |
| 1 |
Core combination method |
Treat blood-borne tumors; administer effective thalidomide amount + dexamethasone |
| 2 |
Dose range |
Thalidomide: 0.1 to 300 mg/kg/day |
| 3 |
Narrower dose range |
Thalidomide: 0.5 to 50 mg/kg/day |
| 4 |
Narrowest dose range |
Thalidomide: 1 to 10 mg/kg/day |
| 5 |
Route limitation |
Thalidomide + dexamethasone are parenteral |
| 6 |
Route limitation |
Thalidomide + dexamethasone are oral |
How broad is claim 1, and what does it cover?
Claim 1 covers a method of treating blood-borne tumors where a clinician or sponsor “administers” to a patient:
- An effective amount of thalidomide
- In combination with dexamethasone
- For the indication of blood-borne tumors
Scope implications of claim 1
- Combination required: A practice that uses thalidomide alone is outside claim 1. A practice that uses dexamethasone alone is outside claim 1. A practice that uses thalidomide + dexamethasone for the stated purpose lands in-scope, assuming the patient has a “blood-borne tumor” as that phrase is interpreted under the patent.
- No route restriction in claim 1: Routes are addressed only in dependent claims (5 and 6). That means claim 1 is directionally broad across administration routes as long as the combination is administered.
- No schedule restriction in claim 1: The provided claim language does not specify dosing frequency, timing between drugs, or cycle structure. Unless constrained elsewhere in the specification, infringement analysis typically turns on whether the combination is used as a regimen.
- No drug-form restriction in claim 1: No requirement for crystalline form, salt form, specific excipients, or controlled release appears in the claims you provided.
What do the dependent claims narrow (and why they matter in enforcement)?
Dependent claims convert claim 1 into progressively narrower sub-classes that may matter in both infringement and freedom-to-operate (FTO) posture.
Claims 2 to 4: thalidomide dose ranges
These create dose-window “landing zones”:
- Claim 2: 0.1 to 300 mg/kg/day
- Claim 3: 0.5 to 50 mg/kg/day
- Claim 4: 1 to 10 mg/kg/day
Practical boundary effect:
If an accused regimen uses thalidomide outside these ranges, it may avoid those dependent claims. However, it can still potentially infringe claim 1 if the “effective amount” element is met and the regimen uses thalidomide + dexamethasone for blood-borne tumors.
Claims 5 and 6: administration route
- Claim 5: both thalidomide and dexamethasone administered parenterally
- Claim 6: both administered orally
Practical boundary effect:
If an accused regimen mixes routes (for example, oral dexamethasone with parenteral thalidomide), it may avoid claim 5 or 6 while still being vulnerable under claim 1, since claim 1 does not require route uniformity.
Where are the key legal and technical “pressure points” in the claim language?
The claim set you provided is short, which makes the following elements central to scope:
1) “blood-borne tumors”
This is the therapeutic target limitation. The scope depends on how the term is construed:
- It likely covers hematologic malignancies (the natural reading)
- It may include cancers located in blood and blood-forming systems
- It may exclude solid tumors unless “blood-borne” is interpreted broadly in light of the specification
2) “treating”
This term typically captures any clinical objective consistent with the patent’s disclosure. The claim does not define endpoints such as response rate, survival, MRD, or tumor reduction, so “treating” is usually broad, subject to doctrine of claim construction.
3) “effective amount”
This introduces an interpretive issue:
- The dependent dose ranges provide numeric anchoring.
- But even outside the numeric ranges, claim 1 can still be implicated if the dosing is an “effective amount” and the clinician’s intended treatment is within the “blood-borne tumors” scope.
What is the patent’s likely positioning in the broader thalidomide + steroid combination landscape?
From a competitive standpoint, US 7,435,745 is a combination-regimen method patent. That typically places it in a family of claims around:
- repurposing or expanding use of thalidomide in hematologic settings
- pairing thalidomide with a corticosteroid (here, dexamethasone)
- defining administration concepts (route) and dosage bands
Common competitive design-around routes
Without introducing additional variables beyond your provided claims, typical competitive strategies that map directly to the claim boundaries are:
- Avoid the required combination: use thalidomide with a different steroid, or thalidomide with no steroid, for the same indication.
- Avoid the claimed routes (dependent claims only): use mixed routes to evade claims 5 and 6 while leaving claim 1 as the main risk.
- Avoid the dependent dose bands: select dosing outside 0.1 to 300 mg/kg/day (claim 2) or outside 0.5 to 50 mg/kg/day (claim 3) or outside 1 to 10 mg/kg/day (claim 4). This may reduce risk for dependent claims but not necessarily claim 1 if “effective amount” still applies.
What cannot be designed around easily
- If competitors use thalidomide + dexamethasone together as a regimen for hematologic malignancies, claim 1 remains a structural obstacle because it is not limited by dose in the independent claim and not limited by route.
How should you evaluate infringement risk by regimen structure?
A clean way to structure infringement analysis is to map an accused regimen against each element.
Element-by-element infringement checklist
| Element |
Covered by |
| Patient has “blood-borne tumor” |
Claim 1 only (via the therapeutic target) |
| Administer thalidomide |
Claim 1 and dependent dose claims |
| Administer dexamethasone in combination |
Claim 1 |
| Thalidomide is “effective amount” |
Claim 1 |
| Dosing falls into numeric bands |
Claims 2-4 (dependent) |
| Route is parenteral or oral for both drugs |
Claims 5-6 (dependent) |
Regimen scenarios (high-level)
| Scenario |
Claim 1 risk |
Dependent claim risk |
| Thalidomide + dexamethasone for blood-borne tumor |
High |
Dose and route dependent |
| Thalidomide alone |
Low to none |
None (combination missing) |
| Dexamethasone alone |
Low to none |
None (thalidomide missing) |
| Thalidomide + different steroid (not dexamethasone) |
Low to none |
None (wrong steroid) |
| Thalidomide + dexamethasone, but for a non–blood-borne tumor |
Lower |
None if “blood-borne tumor” construction excludes it |
| Oral thalidomide + parenteral dexamethasone |
Claim 1 still possible |
Avoids claim 5 and 6 if both must match the route language |
| Dose outside 0.1-300 mg/kg/day |
Claim 1 still possible |
Avoids claims 2-4 if “effective amount” does not establish equivalency within numeric constraints |
Competitive patent landscape: what other claim “types” usually coexist and how this one fits
With only the provided claims, the safest landscape characterization is by claim-type, not by guessing family members or citing unprovided numbers.
Claim-type clusters that typically surround this space
-
Method-of-use combination claims
- Regimen-based: drug A + drug B for a tumor type
- Often include dose windows and routes (as here)
-
Formulation and dosage-form claims
- Controlled release, particle size, polymorphs, salt forms
- Less likely to be necessary for this patent because the independent claim is method-of-treatment
-
Dose and schedule method claims
- Specific frequency, cycle dosing, ramp-up/taper rules
- Your claims do not show schedule specificity, suggesting that enforcement relies on combination + target + dose/route dependent limitations
-
Alternative comparator claims
- Thalidomide with a different steroid or different partner therapy
- These can be design-arounds relative to dexamethasone-specific language
Where US 7,435,745 likely exerts leverage
- It blocks the specific regimen: thalidomide + dexamethasone for blood-borne tumors, especially where dosing or route aligns with dependent claims.
- It is less relevant where clinicians substitute dexamethasone with another steroid, eliminate steroids, change the hematologic indication framing, or materially change the thalidomide dosing approach outside effective and/or claimed windows.
Scope map you can use for portfolio decisions
This map ties claim language to actionable design and litigation/invalidation targets.
Scope map
| Decision lever |
If changed, what claim element is affected? |
Expected impact |
| Replace dexamethasone with another corticosteroid |
“in combination with dexamethasone” |
Avoids claim 1 (combination element fails) |
| Remove dexamethasone |
“in combination with dexamethasone” |
Avoids claim 1 |
| Treat a different tumor category than “blood-borne tumors” |
therapeutic target |
Potential avoidance of claim 1 depending on construction |
| Change route of either drug |
route-limited dependent claims |
Avoids claim 5 and/or 6, claim 1 remains |
| Use thalidomide outside dose windows |
dependent numeric dose claims |
Avoids claims 2-4; claim 1 still depends on “effective amount” |
| Use thalidomide + dexamethasone at effective dose within ranges |
combination + effective + target |
Higher infringement risk across claims 1-6 |
Key Takeaways
- US 7,435,745 is a regimen method patent: it claims treating blood-borne tumors by administering thalidomide in combination with dexamethasone.
- Claim 1 is the core barrier: it is not limited by dose or route in the text you provided, so it is broad relative to the dependent claims.
- Claims 2-4 narrow on thalidomide dose (0.1-300, 0.5-50, 1-10 mg/kg/day), and claims 5-6 narrow on matching administration routes (both parenteral or both oral).
- The most durable design-around is changing the steroid partner (dexamethasone) or avoiding “blood-borne tumors” as the target; route and dose can reduce risk but do not necessarily eliminate claim 1 exposure.
FAQs
-
Does claim 1 require a specific dosing route?
No. Route limitations appear only in dependent claims 5 and 6.
-
Can a regimen infringe claim 1 even if thalidomide dosing is outside the numeric ranges of claims 2-4?
Yes. Claim 1 uses an “effective amount” concept and does not require the specific dose bands shown in claims 2-4.
-
Does claim 5 require both drugs to be parenteral?
Yes. The language you provided requires thalidomide and dexamethasone to be administered parenterally.
-
What is the most direct way to avoid all claims based on the provided text?
Do not administer thalidomide in combination with dexamethasone for blood-borne tumors.
-
If a regimen uses oral dexamethasone and parenteral thalidomide, does it avoid claims 5 and 6?
It avoids either dependent route-limited claim if both drugs must share the same route as written, but claim 1 can still apply.
References
[1] US Patent 7,435,745, claims 1-6 (as provided in the prompt).
